MX369508B - Derivados de tio novedosos que tienen lactamas como potentes inhibidores de hdac y sus usos como medicamentos. - Google Patents
Derivados de tio novedosos que tienen lactamas como potentes inhibidores de hdac y sus usos como medicamentos.Info
- Publication number
- MX369508B MX369508B MX2014003334A MX2014003334A MX369508B MX 369508 B MX369508 B MX 369508B MX 2014003334 A MX2014003334 A MX 2014003334A MX 2014003334 A MX2014003334 A MX 2014003334A MX 369508 B MX369508 B MX 369508B
- Authority
- MX
- Mexico
- Prior art keywords
- lactams
- medicaments
- hdac inhibitors
- derivatives bearing
- thio derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/69—Two or more oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
- C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
- C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D207/28—2-Pyrrolidone-5- carboxylic acids; Functional derivatives thereof, e.g. esters, nitriles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/78—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/94—Oxygen atom, e.g. piperidine N-oxide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
La presente invención se refiere a compuestos novedosos amida de fórmula (I) y su uso como agentes anti tumorales y agentes pro-apoptóticos. La invención incluye el uso de dichos compuestos en medicina, en relación con la enfermedad del cáncer, así como otras enfermedades donde una inhibición de la HDAC es responsiva y la composición farmacéutica que contiene dichos compuestos. (Ver Fórmula).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11181832 | 2011-09-19 | ||
PCT/EP2012/068230 WO2013041480A1 (en) | 2011-09-19 | 2012-09-17 | New thio derivatives bearing lactams as potent hdac inhibitors and their uses as medicaments |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2014003334A MX2014003334A (es) | 2014-05-21 |
MX369508B true MX369508B (es) | 2019-11-11 |
Family
ID=46888433
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014003334A MX369508B (es) | 2011-09-19 | 2012-09-17 | Derivados de tio novedosos que tienen lactamas como potentes inhibidores de hdac y sus usos como medicamentos. |
Country Status (20)
Country | Link |
---|---|
US (1) | US8927533B2 (es) |
EP (1) | EP2758371B1 (es) |
JP (1) | JP6053795B2 (es) |
KR (1) | KR101929774B1 (es) |
CN (1) | CN103732577B (es) |
AU (1) | AU2012311640B2 (es) |
BR (1) | BR112014006600B1 (es) |
CA (1) | CA2843211C (es) |
DK (1) | DK2758371T3 (es) |
EA (1) | EA023171B1 (es) |
ES (1) | ES2579321T3 (es) |
HU (1) | HUE029687T2 (es) |
IL (1) | IL230717A (es) |
MX (1) | MX369508B (es) |
NZ (1) | NZ620336A (es) |
PL (1) | PL2758371T3 (es) |
PT (1) | PT2758371T (es) |
UA (1) | UA111231C2 (es) |
WO (1) | WO2013041480A1 (es) |
ZA (1) | ZA201402790B (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CR20160308A (es) * | 2013-12-03 | 2016-11-08 | Acetylon Pharmaceuticals Inc | Combinaciones de inhibidores de histona deacetilasa y farmacos inmunomoduladores |
EP3125920B1 (en) | 2014-04-04 | 2020-12-23 | Del Mar Pharmaceuticals | Dianhydrogalactitol, diacetyldianhydrogalactitol or dibromodulcitol to treat non-small-cell carcinoma of the lung and ovarian cancer |
WO2016201374A1 (en) * | 2015-06-11 | 2016-12-15 | University Of Florida Research Foundation, Incorporated | Sulfanide adenosine derivatives and uses thereof |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1231477B (it) * | 1989-07-12 | 1991-12-07 | Sigma Tau Ind Farmaceuti | (pirrolidin-2-one-1-il) acetammidi quali attivatori dei processi di apprendimento e della memoria e composizioni farmaceutiche comprendenti tali composti |
IT1244507B (it) * | 1991-04-11 | 1994-07-15 | Sigma Tau Ind Farmaceuti | Derivati dell'acido piroglutammico quali attivatori dei processi di apprendimento e della memoria e composizioni farmaceutiche comprendenti tali composti |
EP1231919B1 (en) * | 1999-09-08 | 2015-09-30 | Sloan-Kettering Institute For Cancer Research | Derivatives of 1-amino-1-(hetero)arylaminocarbonyl-6-hydroxyaminocarbonylhexane useful in the treatment of tumors |
ITRM20010464A1 (it) * | 2001-07-31 | 2003-01-31 | Sigma Tau Ind Farmaceuti | Derivati retinoidi ad attivita' antiangiogenica, antitumorale e pro-apoptotica. |
US7163937B2 (en) * | 2003-08-21 | 2007-01-16 | Bristol-Myers Squibb Company | Cyclic derivatives as modulators of chemokine receptor activity |
WO2005051901A1 (en) * | 2003-11-28 | 2005-06-09 | The University Of Queensland | Anti-cancer agents |
AU2004308619A1 (en) * | 2003-12-19 | 2005-07-14 | Jerini Ag | Compounds for the inhibition of undesired cell proliferation and use thereof |
JP2007238452A (ja) | 2006-03-03 | 2007-09-20 | Nippon Kayaku Co Ltd | ヒストン脱アセチル化酵素を阻害する新規化合物 |
EP2100879A1 (en) * | 2008-03-13 | 2009-09-16 | 4Sc Ag | Novel N-substituted tetrahydroisoquinoline/isoindoline hydroxamic acid compounds |
-
2012
- 2012-09-17 WO PCT/EP2012/068230 patent/WO2013041480A1/en active Application Filing
- 2012-09-17 DK DK12761967.4T patent/DK2758371T3/en active
- 2012-09-17 CA CA2843211A patent/CA2843211C/en active Active
- 2012-09-17 NZ NZ620336A patent/NZ620336A/en unknown
- 2012-09-17 JP JP2014530260A patent/JP6053795B2/ja active Active
- 2012-09-17 BR BR112014006600-0A patent/BR112014006600B1/pt active IP Right Grant
- 2012-09-17 ES ES12761967.4T patent/ES2579321T3/es active Active
- 2012-09-17 EP EP12761967.4A patent/EP2758371B1/en active Active
- 2012-09-17 AU AU2012311640A patent/AU2012311640B2/en active Active
- 2012-09-17 EA EA201400365A patent/EA023171B1/ru unknown
- 2012-09-17 UA UAA201404167A patent/UA111231C2/uk unknown
- 2012-09-17 HU HUE12761967A patent/HUE029687T2/en unknown
- 2012-09-17 MX MX2014003334A patent/MX369508B/es active IP Right Grant
- 2012-09-17 PL PL12761967T patent/PL2758371T3/pl unknown
- 2012-09-17 KR KR1020147003177A patent/KR101929774B1/ko active IP Right Grant
- 2012-09-17 PT PT127619674T patent/PT2758371T/pt unknown
- 2012-09-17 US US14/236,359 patent/US8927533B2/en active Active
- 2012-09-17 CN CN201280039630.9A patent/CN103732577B/zh active Active
-
2014
- 2014-01-29 IL IL230717A patent/IL230717A/en active IP Right Grant
- 2014-04-16 ZA ZA2014/02790A patent/ZA201402790B/en unknown
Also Published As
Publication number | Publication date |
---|---|
IL230717A0 (en) | 2014-03-31 |
ES2579321T3 (es) | 2016-08-09 |
MX2014003334A (es) | 2014-05-21 |
BR112014006600A2 (pt) | 2017-03-28 |
AU2012311640A1 (en) | 2014-02-13 |
CN103732577B (zh) | 2017-04-05 |
EP2758371B1 (en) | 2016-06-15 |
EA023171B1 (ru) | 2016-04-29 |
UA111231C2 (uk) | 2016-04-11 |
DK2758371T3 (en) | 2016-08-01 |
EA201400365A1 (ru) | 2014-06-30 |
CA2843211A1 (en) | 2013-03-28 |
US20140200205A1 (en) | 2014-07-17 |
WO2013041480A1 (en) | 2013-03-28 |
BR112014006600B1 (pt) | 2022-04-19 |
HUE029687T2 (en) | 2017-03-28 |
KR20140066993A (ko) | 2014-06-03 |
CA2843211C (en) | 2019-03-12 |
US8927533B2 (en) | 2015-01-06 |
IL230717A (en) | 2017-01-31 |
PL2758371T3 (pl) | 2017-01-31 |
PT2758371T (pt) | 2016-07-13 |
NZ620336A (en) | 2015-07-31 |
JP6053795B2 (ja) | 2016-12-27 |
KR101929774B1 (ko) | 2018-12-18 |
AU2012311640B2 (en) | 2017-04-13 |
CN103732577A (zh) | 2014-04-16 |
JP2014531441A (ja) | 2014-11-27 |
EP2758371A1 (en) | 2014-07-30 |
ZA201402790B (en) | 2015-12-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022010520A (es) | Macrociclos peptidicos contra acinetobacter baumannii. | |
GEP20146146B (en) | Pyrrolopyrimidine compounds as inhibitors of cdk4/6 | |
MX2015003653A (es) | Derivados de amida del acido benzoimidazol-carboxilico como moduladores del receptor apj. | |
JO3781B1 (ar) | مشتقات الكينولون | |
PH12014501514A1 (en) | New azetidine derivatives, pharmaceutical compositions and uses thereof | |
MX2015010971A (es) | Derivado novedoso de pirazol. | |
HK1138840A1 (en) | Azabiphenylaminobenzoic acid derivatives as dhodh inhibitors | |
GEP20146125B (en) | Aminopyrimidines as syk inhibitors | |
UA104489C2 (uk) | Сполуки для лікування дисліпідемії та споріднених хвороб | |
MY153258A (en) | Pyrazinone derivatives and their use inthe threatment of lung diseases | |
PH12016500885A1 (en) | Novel heterocyclic compounds | |
IN2014MN02106A (es) | ||
BR112014001801A2 (pt) | indazóis | |
TW200738653A (en) | Anthranilamide/2-amino-heteroarene carboxamide derivatives | |
ATE500222T1 (de) | Benzamid- und heteroarenderivate als cetp- inhibitoren | |
MX342924B (es) | Nuevos compuestos disustituidos de 3,4-diamino-3-ciclobuteno-1,2-d iona para uso en el tratamiento de patologias mediadas por quimiocinas. | |
UA107183C2 (uk) | Феніламіно-ізонікотинамідні сполуки, їх застосування, фармацевтична композиція, що їх містить, та спосіб лікування гіперпроліферативних захворювань | |
IN2012DN02502A (es) | ||
MX2011013869A (es) | Agentes antihelminticos y su uso. | |
PH12014501943A1 (en) | Novel compounds for the treatment of dyslipidemia and related diseases | |
MX2014003334A (es) | Derivados de tio novedosos que tienen lactamas como potentes inhibidores de hdac y sus usos como medicamentos. | |
MX2013003736A (es) | Novedosos agonistas del receptor de la proteina g 119. | |
IL191670A0 (en) | Compounds for the inhibition of apoptosis | |
MX2012007253A (es) | Derivados triciclicos y sus usos y composiciones farmaceuticas. | |
IN2014MN02433A (es) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GB | Transfer or rights |
Owner name: ALFASIGMA S.P.A. |
|
FG | Grant or registration |